Updates are available Correction dated 2024-11-18
Click to view Correction: https://doi.org/10.1038/s41416-024-02836-y
-
Authors
Sasieni, Peter https://orcid.org/0000-0003-1509-8744
Smittenaar, Rebecca
Hubbell, Earl
Broggio, John
Neal, Richard D.
Swanton, Charles https://orcid.org/0000-0002-4299-3018
- License Information
-
More Information
Article History
Received: 3 January 2023
Revised: 14 March 2023
Accepted: 17 March 2023
First Online: 25 April 2023
Change Date: 18 November 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41416-024-02836-y
Competing interests
: PS is a paid member of GRAIL’s Scientific Advisory Board and the Director of the The Cancer Research UK and King’s College London Cancer Prevention Trials Unit that is contracted by GRAIL, LLC, to run the NHS-Galleri trial, is on the Medical Advisory Committee for NSV, and has received consultant fees from Roche. RS and EH are employees of GRAIL Bio UK Ltd, and hold stock in Illumina, Inc.; RS also has contingent value rights in GRAIL. JB is employed by NHS Digital and is an Associate Research Fellow (honorary) at the Nuffield Department for Population Health, University of Oxford. RDN provides his services as Co-Chief Investigator to the NHS-Galleri trial through university consultancy funded by GRAIL, LLC, to the University of Exeter; both he and the University of Exeter financially benefit from this partnership. CS provides his services as Co-Chief Investigator to the NHS-Galleri trial through university consultancy funded by GRAIL, LLC, to University College London Business, for another study; is an AstraZeneca advisory board member and Chief Investigator for the AZ MeRmaiD 1 and 2 clinical trials; CS is a paid member of GRAIL’s Scientific Advisory Board (SAB); received grant funding from AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Pfizer, Roche-Ventana, Invitae, and Ono Pharmaceutical; receives consultant fees from Achilles Therapeutics (also SAB member), Genentech, Medixci, Roche Innovation Centre Shanghai, Bicycle Therapeutics (also SAB member), Metabomed (until July 2022), and the Sarah Cannon Research Institute; has received honoraria from Amgen, AstraZeneca, Pfizer, Novartis, GlaxoSmithKline, MSD, Bristol Myers Squibb, Illumina, and Roche-Ventana; had stock options in Apogen Biotechnologies and GRAIL until June 2021; currently has stock options in Epic Bioscience, Bicycle Therapeutics, and Achilles Therapeutics; and is co-founder of Achilles Therapeutics.
: Not applicable.
